



UNIVERSITI PUTRA MALAYSIA

**ONCOLYTIC EFFECT OF NEWCASTLE DISEASE VIRUS ON THE
MCF-7 AND MDA-MB-231 BREAST CANCER CELL LINES**

NARAYANI MEYYAPPAN

FPSK (M) 2003 16

**ONCOLYTIC EFFECT OF NEWCASTLE DISEASE VIRUS ON THE MCF-7
AND MDA-MB-231 BREAST CANCER CELL LINES**

By

NARAYANI MEYYAPPAN

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,
in Fulfilment of the Requirement for the Degree of Master of Science**

August 2003



This thesis is especially dedicated to:

My parents, who are infinitely precious to me

**My brother-in law, sisters and niece, who have filled
my life with joy and happiness,**

And

To Assoc. Prof. Dr. Fauziah Othman

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Master of Science

**ONCOLYTIC EFFECT OF NEWCASTLE DISEASE VIRUS ON THE MCF-7
AND MDA-MB-231 BREAST CANCER CELL LINES**

By

NARAYANI MEYYAPPAN

August 2003

Chairman: Associate Professor Fauziah Othman, Ph.D.

Faculty: Medical and Health Sciences

The study was conducted to find a new anti-cancer agent for the treatment of breast cancer. The oncolytic effect of Newcastle disease virus (NDV) on MCF-7 and MDA-MB-231 breast cancer cell lines was investigated using various methods. The V4-UPM and AF2240 strains of NDV were propagated in the allantoic fluid of 11-days-old embryonated eggs. The allantoic fluid was harvested, purified and stored at -20°C. The haemagglutination (HA) test was conducted on the purified viruses to determine the HA titre of the V4-UPM and AF2240 strains, which were 16 384 and 128 HA units consecutively. The microculture tetrazolium (MTT) assay was carried out to detect the cytotoxic effect of the NDV strains on breast cancer cell lines using monolayer and co-culture techniques to determine the IC₅₀ value. The IC₅₀ values for the MCF-7 treated with V4-UPM strain were 4096 and 128 HA units for the monolayer and co-culture, respectively, while, the MDA-MB-231 had an IC₅₀ value of 96 HA units for both techniques. When treated with AF2240 strain, MCF-7 showed IC₅₀ value of 96 and 64 HA units for the monolayer and co-culture methods, respectively. Whereas, the IC₅₀ value for MDA-MB-231 cells was 4 HA units for both techniques. Further studies were done to observe the ultrastructural changes in the treated cells and viewed under an energy filter transmission electron microscope

filter transmission electron microscope (EFTEM). The morphological features were also observed under a confocal microscope whereby the cells were stained with acridine orange (AO) and propidium iodide (PI). The treated cells showed apoptotic features such as cell shrinkage, nuclear fragmentation, chromatin condensation, cytoplasmic vacuolisation, cell blebbing and formation of apoptotic bodies. However, control cancer cells did not show any prominent changes and intact nucleus and clear cytoplasm were noticed. For the identification of the presence of the NDV, the cells were labelled with a polyclonal antibody and anti-chicken FITC. The NDV was found in the cytoplasm of the MCF-7 and MDA-MB-231 cells and occasionally in the nucleus of the MDA-MB-231 cells at day 3 post-inoculation. The TdT-mediated dUTP nick-end labelling (TUNEL) assay was conducted to specifically label and quantify the percentage of apoptotic cells via lesion scoring under a fluorescence microscope. The statistical analysis using independent t-test revealed that the apoptotic activity of V4-UPM and AF2240 strains on the MCF-7 and MDA-MB-231 cells are significantly different ($p \leq 0.05$) and the susceptibility of these cell lines towards the V4-UPM and AF2240 strains are also significantly different ($p \leq 0.05$). From the data obtained, the AF2240 strain was found to be significantly more effective, while the MDA-MB-231 cells demonstrated to be significantly more responsive towards the NDV strains. These findings confirmed that the mode of cell death induced by the NDV strains is apoptosis. This study also suggests that the V4-UPM and AF2240 strains of NDV can be a potential anti-cancer agent for the treatment of breast cancer.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk Ijazah Master Sains

**KESAN ONKOLITIK VIRUS NEWCASTLE DISEASE TERHADAP MCF-7
DAN MDA-MB-231 SEL-SEL KANSER PAYUDARA**

Oleh

NARAYANI MEYYAPPAN

Ogos 2003

Pengerusi: Profesor Madya Fauziah Othman, Ph.D.

Fakulti: Perubatan dan Sains Kesihatan

Kajian ini dijalankan untuk mencari agen anti-kanser baru bagi merawat kanser payudara. Kesan onkolitik virus Newcastle disease (NDV) terhadap MCF-7 dan MDA-MB-231 sel-sel kanser payudara telah disiasat menggunakan pelbagai kaedah. Virus V4-UPM dan AF2240 NDV telah dipropagasi dalam cecair alantoid telur embrio berusia 11 hari. Cecair alantoid tersebut telah di kumpul, dipurifikasi dan disimpan dalam -20°C . Ujian heamagglutination (HA) telah dilakukan terhadap virus yang dipurifikasi untuk menentukan titer HA bagi virus V4-UPM dan AF2240, iaitu 16 384 HA unit untuk V4-UPM dan 128 HA unit untuk AF2240. Ujian microculture tetrazolium (MTT) telah dijalankan untuk mengenalpasti kesan sitotoksik virus NDV terhadap sel-sel kanser payudara menggunakan 2 kaedah, iaitu kaedah 'monolayer' dan 'co-culture' bagi menentukan nilai IC_{50} . Nilai-nilai IC_{50} sel MCF-7 yang dirawat dengan virus V4-UPM ialah 4096 HA unit untuk kaedah 'monolayer' dan 128 HA unit untuk kaedah 'co-culture'. Sementara, sel MDA-MB-231 mempunyai IC_{50} bernilai 96 HA unit untuk kedua-dua kaedah. Apabila dirawat dengan virus AF2240, sel MCF-7 menunjukkan IC_{50} bernilai 96 HA unit untuk kaedah 'monolayer' dan 64 HA unit untuk kaedah 'co-culture'. Nilai IC_{50} untuk sel MDA-MB-231 pula ialah 4 HA unit untuk kedua-dua kaedah. Kajian selanjutnya

telah dijalankan untuk meneliti perubahan ultrastruktur sel-sel yang dirawat dengan menggunakan mikroskop elektron pancaran penuras tenaga (EFTEM). Ciri-ciri morfologi juga dikaji di bawah mikroskop konfokal dimana sel-sel diwarnakan dengan acridine orange (AO) dan propidium iodide (PI). Sel-sel yang dirawat menunjukkan ciri-ciri apoptotik seperti pengecutan sel, fragmentasi nukleus, pengkondensasian kromatin, pembentukan vakul-vakul sitoplasma, 'blebbing' sel dan pembentukan jasad-jasad apoptotik. Walau bagaimanapun, sel-sel kanser kawalan tidak mempunyai sebarang perubahan yang ketara dan menunjukkan nukleus dan sitoplasma yang sempurna. Untuk mengenalpasti kehadiran NDV, sel-sel dilabel dengan antibody 'anti-chicken' poliklonal dan 'anti-chicken FITC'. NDV telah dikesan di dalam sitoplasma sel-sel MCF-7 dan MDA-MB-231 dan kadangkala kadang didapati di dalam nukleus sel MDA-MB-231 pada hari ketiga inokulasi. Ujian 'TdT-mediated dUTP nick-end labelling' (TUNEL) telah dilakukan untuk melabel secara spesifik dan mengkuantifikasi peratus sel-sel apoptotik melalui kaedah skor lesi dengan menggunakan mikroskopi floresens. Analisis statistik menggunakan 'independent t-test' menunjukkan bahawa aktiviti apoptotik virus V4-UPM dan AF2240 terhadap sel-sel MCF-7 dan MDA-MB-231 adalah berbeza secara signifikan ($p \leq 0.05$) dan sensitiviti sel-sel ini terhadap virus V4-UPM dan AF2240 adalah juga berbeza secara signifikan ($p \leq 0.05$). Dari maklumat yang diperolehi, kesan virus AF2240 didapati lebih secara signifikan, sementara, sel MDA-MB-231 menunjukkan bahawa ia lebih reaktif terhadap virus NDV. Penemuan ini mengesahkan bahawa mod kematian sel yang dirangsang oleh virus NDV ialah apoptosis. Kajian ini juga mencadangkan bahawa virus V4-UPM dan AF2240 NDV boleh menjadi agen anti-kanser yang berpotensi untuk rawatan kanser payudara.

ACKNOWLEDGEMENTS

I would like to take this opportunity to thank the most important people who have helped me throughout the completion of my Masters' thesis successfully. Without them, this project would not have been possible.

First of all, I owe my indebtedness to my wonderful supervisor, Assoc. Prof. Dr. Fauziah Othman for introducing me to this field and also for giving me personal attention, excellent advice, guidance, encouragement and support throughout my research. I also would like to thank my co-supervisors, Assoc. Prof. Dr. Abdul Rahman Omar and Prof. Dr. Aini Ideris for their invaluable comments and suggestions. They were always available for me when needed. I have been fortunate to receive sponsorship from Majlis Kanser Nasional (MAKNA) for my Masters' programme and would like to extend my sincere thanks to MAKNA, particularly to Yg. Berbahagia Dato' Mohd. Farid Ariffin, President of MAKNA and Yg. Berbahagia Dato' P. Venugopal, the Chief Executive Officer of MAKNA.

I would also like to acknowledge with sincere gratitude all staffs of Microscopy and Microanalysis Unit, Laboratory of Enzyme and Microbial Technology, Institute of Bioscience, UPM, especially to Mr. Ho Oi Kuan, Miss Azilah Abd. Jalil, Miss Noraini Mohd. Ain, Madam Faridah Akmal Ismail and Mr. Rafiuz Zaman Harun for guiding me in the usage of the energy filter transmission electron microscope (EFTEM) and confocal microscope. Special thanks to Dr. Johnson Stanslas, Ajantha Sinniah and Madihah Zawawi for providing me the breast cancer cell lines for my

research. I would also like to thank Madam Hjh. Rodiah Husin from the Biologics Laboratory for her technical assistance for the propagation of the virus.

I am grateful to my laboratory mates, especially to Haryati Shila Hj. Mohd. Wali and Siti Hasmah Mohtar for assisting me in various ways in my laboratory work and for giving me motivation. Appreciation also goes to Madam Susi Edrini for guiding me with the TUNEL method and Mr. Siva Rao Subramaniam for helping me with the statistical analysis.

I extend my deepest and warmest thanks to my beloved family for being so understanding and for having patience in me. Not forgetting, thanks to all my friends who had always been there for me during the hard times of my research.

Finally, I thank God for His blessings on me.

I certify that an Examination Committee met on 19 August 2003 to conduct the final examination of Narayani Meyyappan on her Master of Science thesis entitled "Oncolytic Effect of Newcastle Disease Virus on the MCF-7 and MDA-MB-231 Breast Cancer Cell Lines" in accordance with Universiti Pertanian Malaysia (Higher Degree) Act 1980 and Universiti Pertanian Malaysia (Higher Degree) Regulations 1981. The committee recommends that the candidate be awarded the relevant degree. Members of the Examination Committee are as follows:

PATIMAH ISMAIL, Ph.D.

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairperson)

FAUZIAH OTHMAN, Ph.D.


Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

ABDUL RAHMAN OMAR, Ph.D.

Associate Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Member)

AINI IDERIS, Ph.D.

Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Member)



GULAM RUSUL RAHMAT ALI, Ph.D.
Professor/Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 30 SEP 2003

This thesis submitted to the senate of Universiti Putra Malaysia has been accepted as fulfilment of the requirement for the degree of Master of Science. The members of the Supervisory Committee are as follows:

FAUZIAH OTHMAN, Ph.D.

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairperson)

ABDUL RAHMAN OMAR, Ph.D.

Associate Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Member)

AINI IDERIS, Ph.D.

Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Member)



AINI IDERIS, Ph.D.
Professor/Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 8 JAN 2009

DECLARATION

I hereby declare that the thesis is based on my original work except for quotations and citations, which have been duly acknowledged. I also declare that it has not been previously or concurrently submitted for any other degree at UPM or other institutions.



NARAYANI MEYYAPPAN

Date: 23.12.2003

TABLE OF CONTENTS

	Page
DEDICATION	ii
ABSTRACT	iii
ABSTRAK	v
ACKNOWLEDGEMENTS	vii
APPROVAL	ix
DECLARATION	xi
LIST OF TABLES	xv
LIST OF FIGURES	xvi
LIST OF ABBREVIATIONS	xviii
 CHAPTER	
 1 INTRODUCTION	 1
 2 LITERATURE REVIEW	 6
2.1 Breast Cancer	6
2.2 Etiology and Risk Factors	6
2.3 Treatments for Breast Cancer	6
2.3.1 Surgery	7
2.3.2 Radiation Therapy	8
2.4 Adjuvant Systemic Treatments	9
2.4.1 Hormonal Therapy	10
2.4.2 Chemotherapy	10
2.4.3 Immunotherapy	12
2.5 Gene Therapy	12
2.6 Viral therapy	13
2.7 Newcastle Disease Virus as an Anti-Cancer Agent	14
2.7.1 Historical Review	16
2.7.2 Oncolytic Mechanism of NDV	16
2.8 Newcastle Disease	17
2.8.1 Overview	17
2.8.2 History of Newcastle Disease	18
2.8.3 Newcastle Disease Virus	18
2.8.4 Pathotypes	19
2.8.5 Haemagglutination	21
2.9 NDV Strains	21
2.9.1 V4-NDV	21
2.9.2 AF2240-NDV	22
2.10 Breast Cancer Cell Lines	22
2.10.1 Introduction	22
2.10.2 MCF-7 Cell Lines	23
2.10.3 MDA-MB-231 Cell Lines	23
2.11 Cell Death	23
2.11.1 Apoptosis	24
2.11.2 Apoptosis and Necrosis	25

2.11.3 Tumour Treatment Based on Apoptosis	27
2.12 Cytotoxicity	27
2.12.1 Microculture Tetrazolium (MTT)-based Cytotoxicity Assay	27
2.13 Terminal Deoxynucleotidyl Transferase-mediated dUTP Nick-end Labelling (TUNEL)	28
2.14 Fluorescein Isothiocyanate (FITC)	28
2.15 Acridine Orange (AO) and Propidium Iodide (PI) Staining	29
3 IDENTIFICATION OF NEWCASTLE DISEASE VIRUS WITH ONCOLYTIC EFFECT ON BREAST CANCER CELLS USING CYTOTOXICITY (MICROCULTURE TETRAZOLIUM) ASSAY	30
3.1 Introduction	30
3.2 Materials and methods	31
3.2.1 Propagation of the Virus	31
3.3 Clarification and Purification of the Virus	33
3.4 Preparation of Chicken Red Blood Cell (RBC) for Virus Titration	34
3.5 Virus Titration using Haemagglutination (HA) Test	35
3.6 Cell Culture	35
3.6.1 Splitting Method	35
3.7 Virus Inoculation Techniques	36
3.7.1 Monolayer Method	36
3.7.2 Co-culture Method	37
3.8 Microculture Tetrazolium (MTT) Assay	37
3.9 Results	38
3.10 Discussion	41
4 ULTRASTRUCTURAL STUDIES ON NEWCASTLE DISEASE VIRUS-INFECTED BREAST CANCER CELLS	44
4.1 Introduction	44
4.2 Materials and Methods	45
4.2.1 Sample Preparation for Transmission Electron Microscopy (TEM)	45
4.3 Results	46
4.3.1 Transmission Electron Microscopy of Control MCF-7 Cells	46
4.3.2 Transmission Electron Microscopy of MCF-7 Cells Treated with V4-UPM Strain of NDV	46
4.3.3 Transmission Electron Microscopy of MCF-7 Cells Treated with AF2240 Strain of NDV	47
4.3.4 Transmission Electron Microscopy of Control MDA-MB-231 Cells	50
4.3.5 Transmission Electron Microscopy of MDA-MB-231 Cells Treated with V4-UPM Strain of NDV	50
4.3.6 Transmission Electron Microscopy of MDA-MB-231 Cells Treated with AF2240 Strain of NDV	50

4.3.4	Transmission Electron Microscopy of Control MDA-MB-231 Cells	50
4.3.5	Transmission Electron Microscopy of MDA-MB-231 Cells Treated with V4-UPM Strain of NDV	50
4.3.6	Transmission Electron Microscopy of MDA-MB-231 Cells Treated with AF2240 Strain of NDV	50
4.4	Discussion	53
5	IMMUNOLABELLING OF NEWCASTLE DISEASE VIRUS (NDV) AND DETECTION OF APOPTOTIC CELLS	56
5.1	Introduction	56
5.2	Materials and Methods	58
5.2.1	Immunolabelling	58
5.2.2	Acridine Orange and Propidium Iodide (AO/PI) Staining	59
5.2.3	TUNEL Assay	60
5.3	Results	62
5.3.1	Confocal Microscopy of Control MCF-7 and MDA-MB-231 Cells Labelled with Polyclonal Antibody Against NDV and Anti-chicken FITC	62
5.3.2	Confocal Microscopy of Treated MCF-7 and MDA-MB-231 Cells Labelled with Polyclonal Antibody Against NDV and Anti-chicken FITC	62
5.3.3	Confocal Microscopy of Control MCF-7 and MDA-MB-231 Cells Stained with Acridine Orange and Propidium Iodide	62
5.3.4	Confocal Microscopy of MCF-7 and MDA-MB-231 Cells Treated with V4-UPM or AF2240 Strains of NDV and Stained with Acridine Orange and Propidium Iodide	62
5.3.5	Confocal Microscopy of Control MCF-7 and MDA-MB-231 Cells Stained by TUNEL technique	63
5.3.6	Confocal Microscopy of Treated MCF-7 and MDA-MB-231 Cells Stained by TUNEL technique	63
5.3.7	Quantification of Apoptotic Cells	70
5.3.8	Statistical Analysis	70
5.4	Discussion	72
6	GENERAL DISCUSSION AND CONCLUSION	77
	REFERENCES	83
	APPENDICES	91
	A: Cell Culture	91
	B: Virus Purification	93
	C: Cytotoxicity (Microculture Tetrazolium) Assay	94
	D: Statistical Analysis	99
	BIODATA OF THE AUTHOR	101

LIST OF TABLES

Table		Page
1	Differential features and significance of apoptosis and necrosis	26
2	HA titre of V4-UPM, S and AF2240 NDV strains	38
3	IC ₅₀ values of MCF-7, MDA-MB-231 and 3T3 cells infected with NDV (V4-UPM strain)	39
4	IC ₅₀ values of MCF-7, MDA-MB-231 and 3T3 cells infected with NDV (AF2240 strain)	39
5	IC ₅₀ values of MCF-7 cells infected with NDV (S, inactivated V4-UPM and inactivated AF2240 strains)	40
6	IC ₅₀ values of MCF-7 and MDA-MB-231 infected with tamoxifen	40
7	Quantification of apoptotic cells (percentage of apoptotic cells)	70
8	The statistical analysis of mean number of apoptotic cells in the effect of V4-UPM and AF2240 strains of NDV on the MCF-7 and MDA-MB-231 breast cancer cell lines	71
9	The statistical analysis of mean number of apoptotic cells in response of the MCF-7 and MDA-MB-231 breast cancer cell lines towards the V4-UPM and AF2240 strains of NDV	71
10	Independent T-Test to differentiate the effect of different strains of NDV on the breast cancer cell lines	99
11	Independent T-Test to differentiate the response of different type of breast cancer cell lines towards different strains of NDV	100

LIST OF FIGURES

Figures		Page
1	Transmission electron micrographs of MCF-7 cells treated with V4-UPM strain of NDV: (a) control (b-d) treated at day 1 (b), day 2 (c) and day 3 (d)	48
2	Transmission electron micrographs of MCF-7 cells treated with AF2240 strain of NDV at day 1 (a), day 2 (b, c) and day 3 (d)	49
3	Transmission electron micrographs of MDA-MB-231 cells treated with V4-UPM strain of NDV: (a) control (b-d) treated at day 1 (b), day 2 (c) and day 3 (d)	51
4	Transmission electron microscopy of MDA-MB-231 cells on treatment with AF2240 strain of NDV at day 1 (a), day 2 (b) and day 3 (c, d)	52
5	Confocal micrographs of MCF-7 cells treated with V4-UPM or AF2240 strains of NDV and labelled with polyclonal antibody against NDV and anti-chicken FITC: (a) control (b-d) treated	64
6	Confocal micrographs of MDA-MB-231 cells treated with V4-UPM or AF2240 strains of NDV and labelled with polyclonal antibody against NDV and anti-chicken FITC: (a) control (b-d) treated	65
7	Confocal micrographs of MCF-7 cells treated with V4-UPM or AF2240 strains of NDV and stained with acridine orange and propidium iodide: (a) control (b-d) treated	66
8	Confocal micrographs of MDA-MB-231 cells treated with V4-UPM or AF2240 strains of NDV stained with acridine orange and propidium iodide: (a) control (b-f) treated	67
9	Confocal micrographs of MCF-7 cells treated with V4-UPM or AF2240 strains of NDV and stained by TUNEL technique: (a) control (b-d) treated at day 1 (b, c) and day 3 (d)	68
10	Confocal micrographs of MDA-MB-231 cells treated with V4-UPM or AF2240 strains of NDV stained by TUNEL technique: (a) control (b-d) treated at day 1 (b) and day 3 (c, d)	69

11	Percentage of cytotoxicity of MCF-7 cells inoculated with V4-UPM strain of NDV in monolayer and co-culture methods	94
12	Percentage of cytotoxicity of MDA-MB-231 cells inoculated with V4-UPM strain of NDV in monolayer and co-culture methods	94
13	Percentage of cytotoxicity of 3T3 cells inoculated with V4-UPM strain of NDV in monolayer and co-culture methods	95
14	Percentage of cytotoxicity of MCF-7 cells inoculated with inactivated V4-UPM strain of NDV in co-culture method	95
15	Percentage of cytotoxicity of MCF-7 cells inoculated with AF2240 strain of NDV in monolayer and co-culture methods	96
16	Percentage of cytotoxicity of MDA-MB-231 cells inoculated with AF2240 strain of NDV in monolayer and co-culture method	96
17	Percentage of cytotoxicity of 3T3 cells inoculated with AF2240 strain of NDV in monolayer and co-culture methods	97
18	Percentage of cytotoxicity of MCF-7 cells inoculated with inactivated AF2240 strain of NDV in co-culture method	97
19	Percentage of cytotoxicity of MCF-7 cells inoculated with S strain of NDV in monolayer method	98
20	Percentage of cytotoxicity of MCF-7 and MDA-MB-231 cells inoculated with tamoxifen in co-culture method	98

LIST OF ABBREVIATIONS

AO	Acridine orange
ATV	Antibiotic-trypsin-versin
bp	Basepair
CO ₂	Carbon dioxide
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
EDTA	Ethylene diamenetetraacetate
ELISA	Enzyme-linked immunosorbent assay
ER	Estrogen receptor
FITC	Fluorescein isothiocynate
HA	Haemagglutination
HCl	Hydrochloric acid
HN	Haemagglutination neurimidase
IC ₅₀	Inhibition concentration at 50 percent
MTT	3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
NaCl	Sodium Chloride
NDV	Newcastle disease virus
NTE	NaCl, Tris-HCL and EDTA
OD	Optical density
PBS	Phosphate buffered saline
pH	Hydrogen ion concentration
PI	Propidium iodide
RBC	Red blood cell
RNA	Ribonucleic acid
rpm	Rotation per minute
SSC	Saline-sodium citrate
TdT	Terminal deoxynucleotidyl transferase
TEM	Transmission electron microscope
TNF	Tumour necrosis factor
TUNEL	Terminal deoxynucleotydil transferase-mediated dUTP nick end-labeling
UPM	Universiti Putra Malaysia
UV	Ultraviolet

CHAPTER 1

INTRODUCTION

Cancer is a group of diseases that cause cells in the body to change and grow out of control. Most types of cancer cells form a lump or mass called a tumour, and are named after the part of the body where the tumour first starts. Breast cancer begins in breast tissue, which is made up of glands for milk production, called lobules, and the ducts that connect lobules to the nipples. The remainder of the breast is made up of fatty, connective, and lymphatic tissue. Most types of tumours that form in the breast are benign. Benign breast tumours are abnormal growths, but they do not grow and spread like cancer, and are not life-threatening. Some breast tumours are cancerous, but are called *in situ*, because they have not spread beyond the area where they began. *In situ* breast cancers are confined within the ducts or lobules of the breast. The majority of these tumours will not progress to become an invasive tumour, and at this early stage, nearly all of these cancers can be cured. However other cancerous breast tumours are invasive, or infiltrating. These cancers start in the ducts or lobules of the breast but have broken through the duct or gland walls to invade the surrounding fatty tissue of the breast. The seriousness of invasive breast cancer is strongly influenced by the stage of the disease, or how far the cancer has spread when it is first diagnosed.

Breast cancer is the most common cancer among woman, and is the main cause of cancer death among women in Malaysia. The rate of the cancer incidence differs between different countries. The highest rate is in America and Europe while the

lowest rate is in Asia and Africa. The estimated breast cancer incidence in Malaysia is about 35 for every 100 000 population in the year 2000 (Yip, 2002). The incidence of breast cancer has been rising for the past two decades, while mortality has remained relatively stable since the 1950s. In 2001, approximately 192 200 new cases of invasive breast cancer were diagnosed among women in America (Thomas *et al.*, 2002).

Important risk factors for female breast cancer include early age at onset of menarche, late age at onset of menopause, first full-term pregnancy after age 30, a history of pre-menopausal breast cancer or of benign proliferative breast disease. Obesity, nulliparity, and urban residence also have been shown to be associated with increased risk of breast cancer (Thomas *et al.*, 2002).

Scientists and research groups are working for the improvement for the treatment of breast cancer. The currently available treatments for breast cancer patients are chemotherapy, hormone therapy and radiotherapy, but they are not always effective and often have unpleasant side effects. The efficacy of the treatment depends on the type and the stage of the cancer. Some research is directed to find better ways to use the available drugs, while other research focused on development of new drugs for the treatment of breast cancer that includes the development of anti-cancer from natural products, cancer vaccines and gene therapy. With the development of advanced molecular biology techniques, viruses of animal origin have been tested for virus therapy of human cancers. The Newcastle disease virus (NDV) has been shown to exhibit outstanding anti-cancer effect on various cancer cells.

NDV is a paramyxovirus that causes Newcastle disease in a wide variety of birds and chickens. This fatal disease is characterised by inflammation of respiratory tract and or either brain or the gastrointestinal tract. NDV can also infect humans, but it is generally not very virulent, causing only mild-flu-like symptoms or conjunctivitis or laryngitis. The perception that NDV can replicate up to 10 000 times better in human cancer cells than in most normal human cells has prompted much interest in this virus as a potential anti-cancer agent. Numerous in-vitro and in-vivo studies have been carried out on the oncolytic activity of NDV, which includes clinical studies in the United States, Germany and Hungary. NDV strains that were used in most of these studies are the 73-T, Ulster, MTH-68, Italien, Hickman and PV701 (Cassel and Garret, 1965; Lorence *et al.*, 1988; Schild *et al.*, 1988; Bohle *et al.*, 1990; Reichard *et al.*, 1992; Csatory *et al.*, 1993; Lorence *et al.*, 1994a; Lorence *et al.*, 1994b; Plaksin *et al.*, 1994; Sinkovics and Hovarth, 1995; Csatory *et al.*, 1999; Anonymous, 2001; Fabian *et al.*, 2001; Phuangsab *et al.*, 2001; Schirrmacher *et al.*, 2001; Washburn and Schirrmacher, 2002).

In this study, the oncolytic effect of a local strain of NDV, which is the AF2240 and two modified vaccine strains, namely V4-UPM and S strains were tested on the breast cancer cell lines in-vitro. These strains of NDV have been characterised by Universiti Putra Malaysia (UPM) researchers. However, no studies have been carried out to investigate the anti-cancer effect of the virus for cancer treatment in Malaysia. According to current literature review, the NDV-based anti-cancer therapies have been reported to be of benefit (Reichard *et al.*, 1992; Csatory *et al.*, 1993; Lorence *et al.*, 1994a; Lorence *et al.*, 1994b; Plaksin *et al.*, 1994; Sinkovics and Hovarth, 1995).

The NDV demonstrated to be a potential anti-cancer agent and it could be the choice of treatment for cancer patients in Malaysia in the future.

A new perspective on anti-cancer therapeutic efficacy and the possibility of new targets for anti-cancer agent is offered by the principle that cytotoxic drugs operate primarily by causing apoptosis in tumour cells and participate in tumour regression. Apoptosis (from the Greek apo: off and ptosis: a falling off or dropping off) is defined as 'a single deletion of scattered cells by fragmentation into membrane-bound particles which are phagocytosed by other cells, believed to be due to programmed cell death (Boise *et al.*, 1995). With the realization of the importance of this process, a variety of techniques have been used to study apoptosis. The process of apoptosis can be used to evaluate drug toxicity and therapeutic efficacy in the studies involving NDV, as a new approach for cancer treatments.

The general objective of this study is to:

Identify a new anti-cancer agent for the treatment of breast cancer.

The specific objectives are to:

- 1) determine the IC_{50} value of the breast cancer cell lines inoculated with NDV strains using the microculture tetrazolium (MTT) assay to evaluate the cytotoxic effect,

- 2) observe the ultrastructural changes of the cells inoculated with NDV strains, under energy filter transmission electron microscope (EFTEM),
- 3) observe the morphological changes of the cells stained with a combination of acridine orange and propidium iodide stains under confocal microscope,
- 4) detect the presence and location of the virus by immunolabelling with a polyclonal antibody and goat-anti-chicken FITC,
- 5) detect DNA strand breaks in apoptotic cells using TUNEL labelling assay (DeadEnd Fluorometric TUNEL System), and
- 6) quantify the percentage of apoptotic cells by conducting lesion scoring under fluorescence microscope and followed by statistical analysis.

CHAPTER 2

LITERATURE REVIEW

2.1 Breast Cancer

Breast cancer is the most frequently diagnosed cancer in women. The incidence of breast cancer has been increasing constantly over the past several decades. The lifetime risk of developing breast cancer is 12.2%, or 1 in 8 women. The lifetime risk of dying of breast cancer is 3.6%, or 1 in 28 women (Dorr, 1998). The incidence of breast cancer is rare below the age of 30 but increases beyond the age of 50, as it continues to rise but more slowly compared to premenopausal women (Taylor *et al.*, 2000).

2.2 Etiology and Risk Factors

About a third of women with breast cancer relate to a family history on one or more first-degree relatives with breast cancer and of these 4 to 9% have hereditary breast cancer. Hereditary breast cancer is, however, believed to be responsible for up to 25% of breast malignancies that occur prior to age 30 (Dorr, 1998).

Factors leading to an increased risk of breast cancer include mutations in the breast cancer susceptibility gene BRCA-1 and BRCA-2. Mutation in these genes causes majority of hereditary breast cancers. However, hereditary breast cancer account for only 5% to 10% of all breast cancers (Taylor *et al.*, 2000).